PTEN and melanoma: Similarly, Nogueira et al. (2010) found that ∼14% of the human melanomas they analyzed had an NRAS mutation in addition to loss of PTEN. It is possible that a small population that harbors both RAS and PTEN mutations has escaped from signaling through the PI3K pathway and instead its tumorigenic properties are driven by the MAPK pathway.